Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis.

Current oncology (Toronto, Ont.)·2026
Same author

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
Same author

Duration of systemic therapy in patients with metastatic <i>EGFR</i>-mutated non-small cell lung cancer and brain metastases.

Translational lung cancer research·2026
Same author

The Time-varying Impact of Pancreas Graft Failure on Mortality and Kidney Graft Outcomes in Simultaneous Pancreas and Kidney Transplantation.

Transplantation direct·2026
Same author

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.

JCO precision oncology·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jan 7, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

650

Ultra- and Moderately Hypofractionated Radiotherapy for Inoperable Cholangiocarcinoma: A Single-Institution

Saheli Saha1,2, Cameron Lee2, Zhihui Amy Liu1,2

  • 1Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada.

Current Oncology (Toronto, Ont.)
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Radiotherapy (RT) alone for inoperable cholangiocarcinoma (CCA) showed a median overall survival of 20 months. Tumor size and biliary complications significantly impacted outcomes, with high rates of intrahepatic progression observed.

Keywords:
SBRTcholangiocarcinomainoperable cholangiocarcinomamoderately hypofractionated RT

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

4.1K

Related Experiment Videos

Last Updated: Jan 7, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

650
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

4.1K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Gastroenterology

Background:

  • Systemic therapy is standard for inoperable cholangiocarcinoma (CCA).
  • Radiotherapy (RT) alone is an alternative for localized, inoperable CCA.
  • Evaluating RT's efficacy and prognostic factors is crucial.

Purpose of the Study:

  • Assess overall survival (OS) and progression-free survival (PFS) in inoperable CCA treated with RT alone.
  • Analyze recurrence patterns and the impact of biliary complications on OS.
  • Identify prognostic factors for outcomes in this patient cohort.

Main Methods:

  • Retrospective review of 56 patients with inoperable CCA treated with RT (≥32.5 Gy BED10) between 2004-2022.
  • Kaplan-Meier survival analysis for OS and PFS.
  • Univariate and multivariable analyses to identify prognostic factors.

Main Results:

  • Median OS was 20 months, median PFS was 10 months.
  • One-year local control was 92.1%, with intrahepatic progression being the most common failure pattern (64.9%).
  • Tumor size was the only significant independent prognostic factor; biliary complications were associated with worse OS.

Conclusions:

  • RT alone can achieve significant local control in inoperable CCA.
  • High rates of intrahepatic recurrence necessitate further investigation into treatment strategies.
  • Biliary-event-free survival may be a valuable clinical endpoint for this disease.